Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.
When top corporate officials began cold-calling federal agencies during the March 2020 pandemic lockdown to see how Eastman Kodak Co., which manufactures chemicals, could help reduce expected shortages of essential medicines, it was a changed company from the consumer photography giant that had come to serve as a lesson in what can go wrong when you are overconfident and slow to adapt.
There was a hunger to find the next new thing for an iconic business that had fallen on hard times,...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
